Other substances

LV::SFL

A candidate COVID-19 vaccine.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Vaccine

Drug status

Experimental

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

LV::S_FL is a non-replicative lentiviral vector experimental vaccine encoding the full-length, membrane-anchored form of SARS-CoV-2 S protein (Ku et al., 2020).

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models Viral vector Animal model In vitro Mixed substance	hACE2 HEK293T cells; C57BL/6J mice; golden hamsters; SARS-CoV-2 strain BetaCoV/France/IDF0372/2020	15.92	Intranasal boosting with the experimental vaccine elicited neutralizing antbody and CD8+ T-cell immune responses, decreased lung viral loads and inflammation in mice. It was also effective in preventing SARS-CoV-2-induced lung injury in golden hamsters.	Dec/16/2020

Export (.csv)